Asif Habib, MD
Psychiatry · Saint Louis, MONPI 1124000104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 862 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,568 and has fallen 59.2% since, to $1,047 in 2025. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 862 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$996
- plus $4K from 22 others
Across 162 payments — averaging $3111.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$303K
- Teva Pharmaceuticals USA, Inc.$144K
- Neurocrine Biosciences, Inc.$32K
- Avanir Pharmaceuticals, Inc.$8K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
- Alkermes, Inc.$4K
- plus $6K from 2 others
What the payments were for
- Food & beverage$13,34099%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 160 | $2,351 |
| Neurocrine Biosciences, Inc. | 109 | $1,932 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 117 | $1,817 |
| Alkermes, Inc. | 79 | $1,247 |
| AbbVie(2 entities) | 96 | $1,069 |
| Sunovion Pharmaceuticals Inc. | 72 | $996 |
| Lundbeck LLC | 48 | $758 |
| Johnson & Johnson | 31 | $617 |
| Teva Pharmaceuticals USA, Inc. | 28 | $538 |
| Eisai Inc. | 33 | $405 |
| Vanda Pharmaceuticals Inc. | 19 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $374 |
| E.r. Squibb & Sons, L.L.C. | 13 | $319 |
| Acadia Pharmaceuticals Inc | 5 | $122 |
| Merck | 5 | $96 |
| Almatica Pharma LLC | 6 | $94 |
| Jazz Pharmaceuticals Inc. | 5 | $77 |
| Orexo US, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Coloplast | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Bausch Health US, LLC | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
| Neuronetics, Inc. | 1 | $13 |
| Indivior Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$126
How this compares
$13,434 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 37 | $103,651 |
| RexultiBrexpiprazole | 88 | $79,121 |
| TrintellixVortioxetine Hydrobromide | 157 | $75,059 |
| Abilify MaintenaAripiprazole | 24 | $74,086 |
| AristadaAripiprazole Lauroxil | 20 | $65,338 |
| CaplytaLumateperone Tosylate | 32 | $54,318 |
| FanaptIloperidone | 15 | $38,095 |
| Clozapine | 267 | $30,635 |
| Lurasidone Hcl | 79 | $25,991 |
| NuedextaDextromethorphan Hbr/Quinidine | 57 | $23,926 |
| Divalproex Sodium | 454 | $22,401 |
| VraylarCariprazine Hcl | 14 | $21,584 |
| Chlorpromazine Hcl | 46 | $18,774 |
| Clozapine OdtClozapine | 13 | $15,129 |
| Divalproex Sodium ErDivalproex Sodium | 155 | $15,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,351 | $153,207112 claims |
| Johnson & JohnsonInvega Sustenna | $617 | $103,65137 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $374 | $75,059157 claims |
| Alkermes, Inc.Aristada | $1,247 | $65,33820 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,817 | $54,31832 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $379 | $38,09515 claims |
| AbbVieVraylar, Fetzima | $1,069 | $35,42242 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $29 | $23,92657 claims |
| Almatica Pharma LLCSertraline Hcl | $94 | $3,107408 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.